Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-10T09:14:48.626Z Has data issue: false hasContentIssue false

28 - Mitoxantrone to treat multiple sclerosis

from Section III - Clinical trials of multiple sclerosis therapies

Published online by Cambridge University Press:  05 December 2011

By
Gilles Edan  and
Emmanuelle Le Page
Edited by
Jeffrey A. Cohen  and
Richard A. Rudick
Jeffrey A. Cohen
Affiliation:
Cleveland Clinic
Richard A. Rudick
Affiliation:
Cleveland Clinic
Get access

Summary

In the Mitoxantrone in Multiple Sclerosis (MIMS) study, patients were enrolled between 1993 and 1997 at 17 centers in Belgium, Germany, Hungary, and Poland, and randomly assigned to treatment with mitox. Cardiac monitoring, electrocardiography (ECG), and left ventricular ejection fraction (LVEF) assessed by echocardiography or radionuclide scan, was performed before treatment. The comparative study of mitox efficacy profile in relapsing-remitting multiple sclerosis (RRMS) and secondary-progressive multiple sclerosis (SPMS) evaluated the clinical and neuroradiological response to mitox. Substantial tolerability data are available from oncology studies in which mitox was generally used in combination with cyclophosphamide, luorouracil, mitomycin, methotrexate, and radiotherapy for leukemia, non-Hodgkin's lymphoma and solid tumors, and from MS studies in which mitox was used as monotherapy. The available data from studies in patients with MS suggest that mitox may have a role to play in the management of aggressive disease, as an induction therapy.

Keywords

randomized placebo-controlled trialsmultiple scleroisisnon-randomized observational trialsretrospective cohort studiesdisease-modifying therapieslong-term follow-upcross-sectional studiescase-control studies
Type
Chapter
Information
Multiple Sclerosis Therapeutics , pp. 344 - 357
Publisher: Cambridge University Press
Print publication year: 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×